Defining the therapeutic window of vertebral photodynamic therapy in a murine pre-clinical model of breast cancer metastasis using the photosensitizer BPD-MA (Verteporfin)
- 429 Downloads
Breast cancer is known to cause metastatic lesions in the bone, which can lead to skeletal-related events. Currently, radiation therapy and surgery are the treatment of choice, but the success rate varies and additional adjuncts are desirable. Photodynamic therapy (PDT) has been applied successfully as a non-radiative treatment for numerous cancers. Earlier work has shown that the athymic rat model is suitable to investigate the effect of PDT on bone metastasis and benzoporphyrin-derivative monoacid ring A (BPD-MA; verteporfin) has been shown to be a selective photosensitizer. The aim of this study was to define the therapeutic window of photosensitizer with regard to drug and light dose. Human breast carcinoma cells (MT-1)—stable transfected with the luciferase gene—were injected intra-cardiacally into athymic rats. At 14 days, the largest vertebral lesion by bioluminescence imaging was targeted for single treatment PDT. A drug escalating-de-escalating scheme was used (starting drug dose and light energy of 0.2 mg/kg and 50 J, respectively). Outcomes included 48 h post-treatment bioluminescence of remaining viable tumour, histomorphometric assessment of tumour burden, and neurologic evaluation. The region of effect by bioluminescence and histology increased with increasing drug dose and light energy. A safe and effective drug-light dose combination in this model appears to be 0.5 mg/kg BPD-MA and applied light energy of less than 50 J for the thoracic spine and 1.0 mg/kg and 75 J for the lumbar spine. For translation to clinical use, it is an advantage that BPD-MA (verteporfin), a second-generation photosensitizer, is already approved to treat age-related macular degeneration. Overall, PDT represents an exciting potential new minimally-invasive local, safe and effective therapy in the management of patients with spinal metastases.
KeywordsSpine Breast cancer Bone metastasis Photodynamic therapy
Funding for this study was generously provided by the Canadian Breast Cancer Foundation, Ontario Chapter through a grant from the National Cancer Institute of Canada. The human breast cancer MT-1 cells were kindly provided by Dr. O. Engebraaten, Norwegian Radium Hospital, Oslo, Norway.
- 10.Allison R, Mang T, Hewson G, Snider W, Dougherty D (2001) Photodynamic therapy for chest wall progression from breast carcinoma is an underutilized treatment modality. Cancer 91:1–8. doi: 10.1002/1097-0142(20010101)91:1<1::AID-CNCR1>3.0.CO;2-P CrossRefPubMedGoogle Scholar
- 16.Akens MK, Yee AJM, Wilson BC, Burch S, Johnson CL, Lilge L, Bisland SK (2007) Photodynamic therapy of vertebral metastases: evaluating tumor-to-neural tissue uptake of BPD-MA and ALA-PpIX in a murine model of metastatic human breast carcinoma. Photochem Photobiol 83:1034–1039. doi: 10.1111/j.1751-1097.2007.00172.x CrossRefPubMedGoogle Scholar
- 18.Parekh SG, Trauner KB, Zarins B, Foster TE, Anderson RR (1999) Photodynamic modulation of wound healing with BPD-MA and CASP. Lasers Surg Med 24:375–381. doi: 10.1002/(SICI)1096-9101(1999)24:5<375::AID-LSM8>3.0.CO;2-B CrossRefPubMedGoogle Scholar
- 25.Hebel R, Stromberg MW (1986) Anatomy and embryology of the laboratory rat. BioMed Verlag, WoerthseeGoogle Scholar
- 26.Burch S, Yee AJM (2005) Role of photodynamic therapy for bone metastasis. In: Singh G, Rabbani SA (eds) Bone metastasis. Humana Press Inc, Totowa, pp 243–253Google Scholar
- 27.Bisland SK, Lilge L, Lin A, Rusnov R, Wilson BC (2004) Metronomic photodynamic therapy as a new paradigm for photodynamic therapy: rationale and preclinical evaluation of technical feasibility for treating malignant brain tumors. Photochem Photobiol 80:22–30. doi: 10.1562/2004-03-05-RA-100.1 CrossRefPubMedGoogle Scholar
- 28.Henderson BW, Gollnick SO, Snyder JW, Busch TM, Kousis PC, Cheney RT, Morgan J (2004) Choice of oxygen-conserving treatment regimen determines the inflammatory response and outcome of photodynamic therapy of tumors. Cancer Res 64:2120–2126. doi: 10.1158/0008-5472.CAN-03-3513 CrossRefPubMedGoogle Scholar
- 33.Cruess AF, Zlateva G, Pleil AM, Wirostko B (2008) Photodynamic therapy with verteporfin in age-related macular degeneration: a systematic review of efficacy, safety, treatment modifications and pharmacoeconomic properties. Acta Ophthalmol (Copenh). doi: 10.1111/j.1755-3768.2008.01218.x